Two teams at the Vagelos College of Physicians and Surgeons received funding from the Chan Zuckerberg Biohub New York to develop next-generation, personalized cell therapies for cancer and autoimmune diseases.

Aimee Payne, chair of the Department of Dermatology, leads a project to develop cell therapies that eliminate harmful cells in patients with pemphigus, myasthenia gravis, and other autoimmune diseases.

Catherine Spina, assistant professor of radiation oncology, and Jeremy Worley, assistant professor of systems biology, lead a team that is working to adapt chimeric antigen receptor T cell (CAR T) therapy—which has shown remarkable success in treating blood cancers—for the treatment of solid tumors.

The researchers are among nine new investigators to receive funding from the Investigator Program(link is external and opens in a new window) at CZ Biohub NY. The program provides unrestricted funding to scientists, engineers, and technologists from Columbia, Rockefeller, and Yale to pursue innovative and high-impact research in systems immunology. CZ Biohub NY launched in 2023 with a mission to harness and bioengineer immune cells for the early detection, prevention, and treatment of a broad spectrum of age-related diseases.

Please access full article on CUIMC site.